Biostage, Inc. announced that Mr. Matthew Dallas and Mr. Jeffrey Young were appointed to its Board of Directors, effective November 6, 2018. Mr. Dallas brings more than 20 years of financial management experience, including 18 years in the life sciences industry. He is currently the CFO of AVEO Oncology. Prior to AVEO, Mr. Dallas served as CFO and Treasurer of CoLucid Pharmaceuticals. Mr. Dallas also previously worked at Genzyme Corporation, NEN Life Sciences, and Kimberly-Clark Corporation where he held various positions of increasing responsibility in finance and accounting. Mr. Young, meanwhile, also brings over 20 years of finance, capital markets, and financial operations experience in the life sciences sector. He is currently the CFO of Axial Biotherapeutics. Prior to Juniper, Mr. Young served as CFO and Treasurer of OvaScience, Transmedics and Lantheus Medical Imaging. He also previously worked at Critical Therapeutics, PerkinElmer, Inc., and PriceWaterhouseCoopers LLP where he held various positions of responsibility in finance and accounting. Mr. Dallas and Mr. Young will both be members of the company's audit committee, of which Mr. Young will also serve as Chairman.